A Phase 4 interventional study of Abatacept and Adalimumab in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 28 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-03.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 75th largest by enrollment, is one of 8 that started in 2015, is one of 38 in phase 4, and was the 85th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 39th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2015, is one of 2 in phase 4, and was the 62nd registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine changes in immune cells and proteins in response to treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus adalimumab, both given in combination with methotrexate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abatacept Single Blind Treatment Period
Drug: Abatacept · Drug: Methotrexate
Adalimumab Single Blind Treatment Period
Drug: Abatacept · Drug: Adalimumab · Drug: Methotrexate
Abatacept Cumulative Treatment Period
Drug: Abatacept
Also known as: Orencia
Also known as: Humira
Percentage of Adverse Events (AEs)
Percentage of participants who experienced an AE
Time frame: up to 85 days post last dose, approximately 40 weeks
Percentage of Participants With an Serious Adverse Events (SAEs)
Percentage of participants who experienced an SAEs
Time frame: up to 85 days post last dose, approximately 40 weeks
Percentage of Participants With Adverse Events Leading to Discontinuation (AEsDc)
Percentage of participants who experienced an (AEsDc)
Time frame: up to 85 days post last dose, approximately 40 weeks
Percentage of Serious Adverse Events Leading to Discontinuation (SAEsDc)
Percentage of participants who experienced an (SAEsDc)
Time frame: up to 85 days post last dose, approximately 40 weeks
Percentage of Drug Related Adverse Events (DRAEs)
Percentage of participants who experienced an DRAEs
Time frame: up to 85 days post last dose, approximately 40 weeks
Percentage of Drug Related Serious Adverse Events (DRSAEs)
Percentage of participants who experienced an DRSAEs
Time frame: up to 85 days post last dose, approximately 40 weeks
Number of Deaths
Number of participants who experienced Death
Time frame: up to 85 days post last dose, approximately 40 weeks
| Milestone | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Started | 40 | 40 | 0 |
| Completed | 40 | 36 | 0 |
| Not completed | 0 | 4 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Request to discontinue | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Milestone | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Started | 40 | 36 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 40 | 36 | 0 |
| Withdrew: Entered cumulative abatacept period | 40 | 36 | 0 |
| Milestone | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Started | 0 | 0 | 76 |
| Completed | 0 | 0 | 72 |
| Not completed | 0 | 0 | 4 |
| Withdrew: Other reasons | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Request to discontinue | 0 | 0 | 1 |
Percentage of participants who experienced an AE
| Percentage of participant with AEs | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Percentage of Adverse Events (AEs) | 55.0 | 70.0 | 57.9 |
Percentage of participants who experienced an SAEs
| Percentage of participants with SAEs | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Percentage of Participants With an Serious Adverse Events (SAEs) | 2.5 | 5.0 | 5.3 |
Percentage of participants who experienced an (AEsDc)
| Percentage of participants with AEsDC | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Percentage of Participants With Adverse Events Leading to Discontinuation (AEsDc) | 0 | 2.5 | 0 |
Percentage of participants who experienced an (SAEsDc)
| Percentage of participants with SAEsDc | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Percentage of Serious Adverse Events Leading to Discontinuation (SAEsDc) | 0 | 2.5 | 0 |
Percentage of participants who experienced an DRAEs
| Percentage of participants with DRAEs | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Percentage of Drug Related Adverse Events (DRAEs) | 30.0 | 27.5 | 22.4 |
Percentage of participants who experienced an DRSAEs
| Percentage of Participants with DRSAEs | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Percentage of Drug Related Serious Adverse Events (DRSAEs) | 0 | 2.5 | 0 |
Number of participants who experienced Death
| Number of Deaths | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Deaths | 0 | 1 | 0 |
Collected over up to 85 days post last dose, approximately 40 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/40 (0%) | 1/40 (2.5%) | 21/40 (52.5%) |
| Treatment B | 1/40 (2.5%) | 2/40 (5%) | 28/40 (70%) |
| Treatment C | 0/76 (0%) | 4/76 (5.3%) | 19/76 (25%) |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Atrial Septal DefectCongenital, familial and genetic disorders | 1/40 | 0/40 | 1/76 |
| Sudden DeathGeneral disorders | 0/40 | 1/40 | 0/76 |
| VaricellaInfections and infestations | 0/40 | 1/40 | 0/76 |
| Cerebral InfarctionNervous system disorders | 1/40 | 0/40 | 1/76 |
| Incision site complicationInjury, poisoning and procedural complications | 0/40 | 0/40 | 1/76 |
| Patella fractureInjury, poisoning and procedural complications | 0/40 | 0/40 | 1/76 |
| Myocardial InfarctionCardiac disorders | 0/40 | 0/40 | 1/76 |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/40 | 14/40 | 10/76 |
| Alanine Aminotransferase IncreasedInvestigations | 3/40 | 6/40 | 9/76 |
| Aspartate Aminotransferase IncreasedInvestigations | 2/40 | 5/40 | 7/76 |
| NasopharyngitisInfections and infestations | 4/40 | 2/40 | 5/76 |
| Urinary Tract InfectionInfections and infestations | 4/40 | 0/40 | 5/76 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/40 | 3/40 | 0/76 |
| Gamma-glutamyltransferase increasedInvestigations | 2/40 | 0/40 | 2/76 |
| HeadacheNervous system disorders | 2/40 | 2/40 | 0/76 |
| LeukopeniaBlood and lymphatic system disorders | 0/40 | 2/40 | 0/76 |
| NeutropeniaBlood and lymphatic system disorders | 0/40 | 2/40 | 0/76 |
All Participants treated in the single-blind period
| Age, Continuous(Years) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Mean | 47.2 ± 12.16 | 44.7 ± 16.30 | — | 46.0 ± 14.35 |
| Sex: Female, Male(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Female | 29 | 31 | — | 60 |
| Male | 11 | 9 | — | 20 |
| Ethnicity (NIH/OMB)(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 6 | — | 10 |
| Not Hispanic or Latino | 16 | 14 | — | 30 |
| Unknown or Not Reported | 20 | 20 | — | 40 |
| Race (NIH/OMB)(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | — | 0 |
| Asian | 0 | 2 | — | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | — | 0 |
| Black or African American | 4 | 1 | — | 5 |
| White | 36 | 36 | — | 72 |
| More than one race | 0 | 0 | — | 0 |
| Unknown or Not Reported | 0 | 1 | — | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Mar 2019, 40 months.
Results were first posted in Sep 2020, 1 year 5 months after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 40 months is above that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate